Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Archemix Outlicenses Aptamers To Ophthotech

This article was originally published in The Pink Sheet Daily

Executive Summary

Ophthotech, a new firm formed by several ex-Eyetech managers, will develop anti-C5 compounds as candidates to treat age-related macular degeneration.
Advertisement

Related Content

Archemix Reduces Aperture to Pursue Orphan Diseases
Ophthotech Will Take Biogen/PDL Drug Volociximab Into The Clinic For AMD
Ophthotech Will Take Biogen/PDL Drug Volociximab Into The Clinic For AMD
Alexion Biologic Soliris Is First To Get FDA Nod For Rare Blood Disease
Alexion Biologic Soliris Is First To Get FDA Nod For Rare Blood Disease
Genentech’s Lucentis Ships June 30 Following Approval
OSI Closes Lid On Eyetech Acquisition

Topics

Advertisement
UsernamePublicRestriction

Register

PS066438

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel